Press Releases - WuXi Biologics
Jan 2, 2025 · Provided as either a standalone service offering or as part of our integrated CMC development platforms, WuXi Biologics provides extensive expertise and industry-leading timelines for cell line engineering and strain development across a wide range of biotherapeutics.
WuXi Biologics
A leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing
WuXi Biologics Announces Proposed Spin-off and Separate Listing …
Hong Kong, China, July 9, 2023 – WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the proposed spin-off and separate listing of its subsidiary WuXi XDC Cayman Inc. (WuXi XDC) on the Main Board of the Hong Kong Stock Exchange.
WuXi Biologics and GSK Enter into License Agreement on Multiple …
Jan 5, 2023 · WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell engaging (TCE) antibody and the option of three additional bi-/multi-specific TCE antibodies developed using WuXi Biologics’ proprietary technology platforms; WuXi Biologics will receive an upfront payment of $40 million and tiered royalties on net ...
Company News: 2023-12 - WuXi Biologics
Our commitment to drive innovation for our clients at the earliest stages of biologics development pertain to both small, venture-backed entities as well as large pharma. Our unique CRDMO model brings us exciting developments in R, D and M in 2023.
WuXi Biologics to Increase Manufacturing Capacity in Germany
Jun 1, 2023 · Leverkusen and Wuppertal, Germany, June 1, 2023 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it will increase manufacturing capacity in Germany.
WuXi Biologics Breaks Ground on CRDMO Center in Singapore
Singapore, March 19, 2024 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has broken ground on its new 13.5-hectare CRDMO center in Tuas Biomedical Park, Singapore.
WuXi Biologics Successfully Implemented a Fully Integrated …
Nov 22, 2023 · As of June 30, 2023, WuXi Biologics is supporting 621 integrated client projects, including 22 in commercial manufacturing. WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector.
WuXi Biologics Germany to Enhance Capabilities with New …
Nov 13, 2024 · Leverkusen, Germany, November 13, 2024 – WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it will enhance its drug product (DP) capabilities at the company’s facility in Leverkusen, Germany, with a new sterile filling line for prefilled ...
WuXi Biologics Successfully Completes First 16,000L …
Dundalk, Ireland, January 31, 2024 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has successfully completed the first manufacturing run at its drug substance facility MFG7, paving the way for large-scale commercial manufacturing ...